Topical Prescription Management.
With recent advances in topical therapies for atopic dermatitis (AD), steroid-sparing options like calcineurin inhibitors, Janus kinase (JAK) inhibitors, and phosphodiesterase-4 (PDE-4) inhibitors are becoming mainstays in therapy, underscoring the importance of careful selection and usage of topical corticosteroids (TCSs) to minimize side effects. Alongside the necessity of emollient use, these steroid-sparing alternatives offer rapid itch relief and efficacy in improving disease severity. While TCSs still hold a prominent role in AD management, promising novel topical treatments like tapinarof and live biotherapeutics to modulate the skin microbiome are also discussed. Overall, the recent addition of novel topical therapies offers diverse options for AD management and underscores the importance of topical treatments in the management of AD.
Duke Scholars
Published In
DOI
ISSN
Publication Date
Volume
Start / End Page
Location
Related Subject Headings
- Skin
- Phosphodiesterase 4 Inhibitors
- Humans
- General & Internal Medicine
- Dermatologic Agents
- Dermatitis, Atopic
- Calcineurin Inhibitors
- Adrenal Cortex Hormones
- Administration, Topical
- Administration, Cutaneous
Citation
Published In
DOI
ISSN
Publication Date
Volume
Start / End Page
Location
Related Subject Headings
- Skin
- Phosphodiesterase 4 Inhibitors
- Humans
- General & Internal Medicine
- Dermatologic Agents
- Dermatitis, Atopic
- Calcineurin Inhibitors
- Adrenal Cortex Hormones
- Administration, Topical
- Administration, Cutaneous